Compartilhar
Informação da revista
Vol. 99. Núm. 6.
Páginas 797-798 (1 novembro 2024)
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Visitas
1841
Vol. 99. Núm. 6.
Páginas 797-798 (1 novembro 2024)
Editorial
Acesso de texto completo
Anais Brasileiros de Dermatologia - Impact Factor and CiteScore for 2023
Visitas
1841
Silvio Alencar Marquesa,
Autor para correspondência
silvio.marques@unesp.br

Corresponding author.
, Ana Maria Ferreira Roselinob, Hiram Larangeira de Almeida Jrc,d, Luciana Patrícia Fernandes Abbadea
a Department of Infectology, Dermatology, Imaging Diagnosis and Radiotherapy, Universidade Estadual Paulista, Botucatu, SP, Brazil
b Department of Internal Medicine, Division of Dermatology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
c Department of Dermatology, Universidade Federal de Pelotas, Pelotas, RS, Brazil
d Department of Dermatology, Universidade Católica de Pelotas, Pelotas, RS, Brazil
Este item recebeu
Informação do artigo
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Texto Completo

The Anais Brasileiros de Dermatologia (ABD) was published for the first time under the name Annaes Brasileiros de Dermatologia e Syphilographia in 1925 and has been published uninterruptedly since then.1 It was indexed in PubMed/Medline in 2009 and the first Impact Factor (IF), published by the Journal of Citation Reports in 2010, corresponded to 0.337. In the following years, the IF increased practically constantly. In 2023, the IF increased to 2.6, corresponding to the highest value in its historical series. And, coherently, the CiteScore for 2023 was 2.4, repeating the 2022 index. In common, even though they use different methodologies, they measure the number of citations received in 2023 by a certain journal, for articles published in the two immediately previous years (IF), or, published in the four immediately previous years (CiteScore). Both metrics, biases aside, reflect the status and scientific hierarchy of scientific journals in the measured period. The ABD evolved in terms of IF, from 50th position out of 70 journals in Dermatology and related areas in 2022, to 34th position out of 94 in 2023. As for CiteScore, it went from the 60th position out of 133 in 2022, to the 71st position out of 142 journals in 2023. Therefore, placing it in Quartile 2 in both metrics it will be of special importance for Capes/MEC (The Brazilian Federal Agency for Support and Evaluation/Ministry of Education) in defining Qualis/ABD in 2024/2025.

Below, for recognition and reflection, are the five articles with the highest rates of citations received in the IF/ABD/2023 composition: 1st - Orofino-Costa R et al.,2 2nd - Bittner GC et al.,3 3rd - Marchioro HZ et al.,4 4th - Barros NM et al. 5 and 5th - Seque MA et al.6

The previously reported numbers and the most cited topics (see references) suggest that ABD has been eclectic and is one of the few journals in general Dermatology to open generous space to infectious diseases, and this sets it apart.7,8

Likewise, the previous numbers reported indicate that the minimum threshold to be considered is IF = 2.6 and reinforces our commitment to constant efforts aimed at improvement and advances. The importance of Brazilian and Latin American Dermatology requires us to do so.

Financial support

None declared.

Authors' contributions

Silvio Alencar Marques: Approval of the final version of the manuscript; drafting and editing of the manuscript.

Ana Maria Roselino: Approval of the final version of the manuscript; drafting and editing the manuscript.

Hiram Larangeira de Almeida Junior: Approval of the final version of the manuscript; drafting and editing of the manuscript.

Luciana P. Fernandes Abbade: Approval of the final version of the manuscript; drafting and editing of the manuscript.

Conflicts of interest

None declared.

References
[1]
S.A. Marques, A.M. Roselino, H.L. Almeida Jr, L.P.F. Abbade.
Anais Brasileiros de Dermatologia: on the eve of its centennial year.
An Bras Dermatol, 99 (2024), pp. 489-490
[2]
R. Orofino-Costa, D.F.S. Freitas, A.E. Bernardes-Engemann, A.M. Rodrigues, C. Talhari, C.E. Ferraz, et al.
Human sporotrichosis: recommendations from the Brazilian Society of Dermatology for the clinical, diagnostic and therapeutic management.
An Bras Dermatol., 97 (2022), pp. 757-777
[3]
G.C. Bittner, F.B. Cerci, E.M. Kubo, S.N. Tolkachjov.
Mohs micrographic surgery: a review of indications, technique, outcomes, and considerations.
An Bras Dermatol., 96 (2021), pp. 263-277
[4]
H.Z. Marchioro, C.C.S. de Castro, V.M. Fava, P.H. Sakiyama, G. Dellatorre, H.A. Miot.
Update on the pathogenesis of vitiligo.
An Bras Dermatol., 97 (2022), pp. 478-490
[5]
N.D. Barros, L.L. Sbroglio, M.D. Buffara, J.L.C.E.S. Baka, A.D. Pessoa, L. Azulay-Abulafia.
Phototherapy.
An Bras Dermatol., 96 (2021), pp. 397-407
[6]
A.C. Seque, M.M.S.S. Enokihara, A.M. Porro, J. Tomimori.
Skin manifestations associated with COVID-19.
An Bras Dermatol., 97 (2022), pp. 75-88
[7]
L.A.R.F. Froes Jr., M.N. Sotto, M.A.B. Trindade.
Leprosy: clinical and immunopathological characteristics.
An Bras Dermatol, 97 (2022), pp. 338-347
[8]
A.C. de Brito, C.M.M. de Oliveira, D.A.A. Unger, M.D.S. Bittencourt.
Cutaneous tuberculosis: epidemiological, clinical, diagnostic and therapeutic update.
An Bras Dermatol., 97 (2022), pp. 129-144

Study conducted at the Department of Infectology, Dermatology, Imaging Diagnosis and Radiotherapy, Universidade Estadual Paulista, Botucatu, SP, Brazil.

Copyright © 2024. Sociedade Brasileira de Dermatologia
Baixar PDF
Idiomas
Anais Brasileiros de Dermatologia (Portuguese)
Opções de artigo
Ferramentas
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.